Corcept Therapeutics Incorporated (CORT)

Corcept Therapeutics (CORT) Q1 2022 Earnings Call Transcript
May 6, 2022 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff On Q4 2021 Results - Earnings Call Tra
Feb. 16, 2022 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics (CORT) Q4 2021 Earnings Call Transcript
Feb. 15, 2022 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Incorporated (CORT) CEO Dr. Joseph Belanoff on Q3 2021 Results - Earnings Call
Nov. 4, 2021 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q3 2021 Earnings Call Transcript
Nov. 3, 2021 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2021 Results - Earnings Call Tra
July 30, 2021 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q2 2021 Earnings Call Transcript
July 30, 2021 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2021 Results - Earnings Call Tra
May 7, 2021 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q1 2021 Earnings Call Transcript
May 7, 2021 | Price: Free! | Source: Motley Fool

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2020 Results - Earnings Call Transcript
Feb. 9, 2021 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q4 2020 Earnings Call Transcript
Feb. 8, 2021 | Price: Free! | Source: Motley Fool

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2020 Results - Earnings Call Transcript
Nov. 7, 2020 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff On Q3 2020 Results - Quick Version Earnings Call T
Nov. 4, 2020 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2020 Results - Earnings Call Transcript
Aug. 5, 2020 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q2 2020 Earnings Call Transcript
Aug. 5, 2020 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q1 2020 Results - Earnings Call Tra
May 5, 2020 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics, Inc. (CORT) CEO Joseph Belanoff on Q4 2019 Results - Earnings Call Transcript
Feb. 21, 2020 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q4 2019 Earnings Call Transcript
Feb. 20, 2020 | Price: Free! | Source: Motley Fool

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2019 Results - Earnings Call Transcript
Nov. 9, 2019 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) Q3 2019 Earnings Call Transcript
Nov. 7, 2019 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Incorporated (CORT) Q2 Earnings Call Transcript
Aug. 3, 2019 | Price: Free! | Source: Motley Fool

Corcept Therapeutics Inc. (CORT) CEO Joseph Belanoff on Q2 2019 Results - Earnings Call Transcript
Aug. 2, 2019 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Inc. (CORT) CEO Joseph Belanoff on Q1 2019 Results - Earnings Call Transcript
May 9, 2019 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Inc. (CORT) CEO Dr. Joseph Belanoff on Q4 2018 Results - Earnings Call Transcr
Feb. 25, 2019 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q3 2018 Results - Earnings Call Tra
Nov. 1, 2018 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics Incorporated (CORT) CEO Joseph Belanoff on Q2 2018 Results - Earnings Call Tra
Aug. 9, 2018 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2017 Results - Earnings Call Transcript
Feb. 22, 2018 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2017 Results - Earnings Call Transcript
Aug. 1, 2017 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q1 2017 Results - Earnings Call Transcript
May 1, 2017 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2016 Results - Earnings Call Transcript
Jan. 30, 2017 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2016 Results - Earnings Call Transcript
Nov. 1, 2016 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2016 Results - Earnings Call Transcript
Aug. 2, 2016 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joe Belanoff on Q1 2016 Results - Earnings Call Transcript
May 3, 2016 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2015 Results - Earnings Call Transcript
Jan. 28, 2016 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2015 Results - Earnings Call Transcript
Nov. 8, 2015 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2015 Results ­ Earnings Call Transcript
Aug. 5, 2015 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q1 2015 Results - Earnings Call Transcript
May 8, 2015 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q4 2014 Results - Earnings Call Transcript
Jan. 29, 2015 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q3 2014 Results - Earnings Call Transcript
Nov. 4, 2014 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q2 2014 Results - Earnings Call Transcript
Aug. 5, 2014 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' (CORT) CEO Joseph Belanoff on Q1 2014 Results - Earnings Call Transcript
May 7, 2014 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript
Jan. 31, 2014 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' CEO Discusses Q3 2013 Results - Earnings Call Transcript
Nov. 9, 2013 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' CEO Discusses Q2 2013 Results - Earnings Call Transcript
Aug. 8, 2013 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
May 2, 2013 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Feb. 14, 2013 | Price: Free! | Source: Seeking Alpha

Corcept Therapeutics' CEO Discusses Q3 2012 Results - Earnings Call Transcript
Nov. 1, 2012 | Price: Free! | Source: Seeking Alpha

Recent filings

Corcept Therapeutics Incorporated's Chief Business Officer just disposed of 35,000 shares - May 19, 2022

Corcept Therapeutics Incorporated's See Remarks was just granted 50,000 options - May 4, 2022

Corcept Therapeutics Incorporated releases salary data. CEO sees compensation rise 90% - April 25, 2022

Corcept Therapeutics Incorporated director just picked up 23,516 shares - March 18, 2022

Corcept Therapeutics Incorporated's Chief Business Officer just disposed of 12,500 shares - March 18, 2022

The Vanguard Group just provided an update on share ownership of Corcept Therapeutics Incorporated - March 9, 2022

Corcept Therapeutics Announces Fourth Quarter And Full-Year 2021 AUDITED FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. - Feb. 15, 2022

Corcept Therapeutics Incorporated Just Filed Its Annual Report: Net Income Per Share... - Feb. 15, 2022

Securities to be offered to employees in employee benefit plans - Feb. 15, 2022

Annual statement of changes in beneficial ownership of securities - Feb. 14, 2022

Corcept Therapeutics Incorporated's Chief Business Officer just disposed of 152 shares - Feb. 14, 2022

G. Leonard Baker, Jr. just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 14, 2022

Corcept Therapeutics Incorporated's Chief Development Officer was just granted 100,000 options - Feb. 11, 2022

Renaissance Technologies LLC just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 11, 2022

Joseph K. Belanoff just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 11, 2022

Corcept Therapeutics Incorporated's Chief Scientific Officer was just granted 200,000 options - Feb. 11, 2022

Corcept Therapeutics Incorporated's Chief Executive Officer was just granted 500,000 options - Feb. 11, 2022

Corcept Therapeutics Incorporated's Chief Commercial Officer was just granted 200,000 options - Feb. 11, 2022

Corcept Therapeutics Incorporated's Chief Financial Officer was just granted 100,000 options - Feb. 11, 2022

Corcept Therapeutics Incorporated's Chief Accounting Officer was just granted 100,000 options - Feb. 11, 2022

Corcept Therapeutics Incorporated's Chief Business Officer was just granted 200,000 options - Feb. 11, 2022

The Vanguard Group just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 9, 2022

INGALLS & SNYDER, LLC just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 4, 2022

BlackRock, Inc. just provided an update on share ownership of Corcept Therapeutics Incorporated - Jan. 28, 2022

Corcept Therapeutics Incorporated's Chief Scientific Officer just picked up 14,650 shares - Jan. 28, 2022

Tender offer statement by Issuer - Dec. 20, 2021

Tender offer statement by Issuer - Dec. 16, 2021

Tender offer statement by Issuer - Dec. 15, 2021

Tender offer statement by Issuer - Dec. 8, 2021

Corcept Therapeutics Announces Extension Of Previously Announced Tender Offer MENLO PARK, Calif., December - Dec. 8, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - Nov. 15, 2021

Tender offer statement by Issuer - Nov. 8, 2021

Corcept Therapeutics Incorporated Just Filed Its Quarterly Report: Net Income Per Share... - Nov. 3, 2021

Corcept Therapeutics Announces Third Quarter Financial Results AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. - Nov. 3, 2021

Corcept Therapeutics Incorporated's Chief Commercial Officer just cashed-in 25,000 options - Oct. 5, 2021

Corcept Therapeutics Incorporated's Chief Business Officer just disposed of 55,000 shares - Sept. 15, 2021

Corcept Therapeutics Incorporated's Chief Commercial Officer just cashed-in 25,000 options - Sept. 3, 2021

Corcept Therapeutics Incorporated director just cashed-in 7,500 options - Sept. 3, 2021

Corcept Therapeutics Incorporated's Chief Development Officer was just granted 500,000 options - Sept. 3, 2021

Corcept Therapeutics Incorporated's Chief Business Officer just picked up 67,210 shares - Sept. 1, 2021

Corcept Therapeutics Incorporated's Chief Development Officer just declared ownership of no shares of Corcept Therapeutics Incorporated - Aug. 19, 2021

Departure of Directors or Certain - Aug. 13, 2021

Corcept Therapeutics Incorporated's Chief Commercial Officer just cashed-in 25,000 options - Aug. 5, 2021

Corcept Therapeutics Incorporated Just Filed Its Quarterly Report: Net Income Per Share... - July 29, 2021

Corcept Therapeutics Announces Second Quarter Financial Results AND PROVIDES CORPORATE UPDATE MENLO PARK, Calif. - July 29, 2021

Corcept Therapeutics Incorporated's Chief Scientific Officer just picked up 19,518 shares - July 16, 2021

Corcept Therapeutics Incorporated's Chief Commercial Officer just picked up 10,000 shares - July 14, 2021

Corcept Therapeutics Incorporated's Chief Commercial Officer just cashed-in 25,000 options - July 9, 2021

Corcept Therapeutics Incorporated director was just granted 60,000 options - July 2, 2021

Corcept Therapeutics Incorporated director just declared ownership of no shares of Corcept Therapeutics Incorporated - June 17, 2021

Corcept Therapeutics Incorporated director just picked up 150,000 shares - June 15, 2021

Corcept Therapeutics Settles Patent Litigation With Sun Pharmaceutical MENLO PARK, Calif. - June 15, 2021

Corcept Therapeutics Appoints Joshua M. Murray To Board Of Directors MENLO PARK, Calif. - June 10, 2021

Corcept Therapeutics Incorporated director just cashed-in 7,500 options - June 4, 2021

Corcept Therapeutics Incorporated director was just granted 20,000 options - May 28, 2021

Statement of changes in beneficial ownership of securities - May 28, 2021

Corcept Therapeutics Incorporated director was just granted 20,000 options - May 28, 2021

Corcept Therapeutics Incorporated director was just granted 20,000 options - May 28, 2021

Statement of changes in beneficial ownership of securities - May 28, 2021

Statement of changes in beneficial ownership of securities - May 28, 2021

Corcept Therapeutics Incorporated director was just granted 20,000 options - May 28, 2021

Statement of changes in beneficial ownership of securities - May 20, 2021

Corcept Therapeutics Incorporated director just picked up 23,516 shares - May 13, 2021

Corcept Therapeutics Provides Clinical Update And Announces First Quarter 2021 Financial Results - May 6, 2021

Corcept Therapeutics Incorporated Just Filed Its Quarterly Report: Net Income Per Share... - May 6, 2021

Corcept Therapeutics Incorporated's Chief Financial Officer just disposed of 10,000 shares - April 27, 2021

Other definitive proxy statements - April 22, 2021

Statement of changes in beneficial ownership of securities - April 16, 2021

Corcept Therapeutics Incorporated director just cashed-in 7,500 options - April 7, 2021

Corcept Therapeutics Incorporated's Chief Accounting Officer just cashed-in 25,000 options - April 5, 2021

Corcept Therapeutics Incorporated's Chief Financial Officer just declared ownership of no shares of Corcept Therapeutics Incorporated - March 3, 2021

Corcept Therapeutics Incorporated's Chief Financial Officer was just granted 400,000 options - March 3, 2021

Corcept Therapeutics Incorporated's Chief Accounting Officer just cashed-in 25,000 options - March 3, 2021

Corcept Therapeutics Incorporated's Chief Business Officer was just granted 40,000 options - March 3, 2021

Corcept Therapeutics: Christopher S. James, Md Director, Investor Relations Corcept Therapeutics - March 1, 2021

Annual report [Section 13 and 15(d), not S-K Item 405] - Feb. 23, 2021

Corcept Therapeutics Announces Fourth Quarter AND FULL-YEAR 2020 AUDITED FINANCIAL RESULTS - Feb. 23, 2021

Securities to be offered to employees in employee benefit plans - Feb. 23, 2021

Corcept Therapeutics Incorporated's See Remarks just cashed-in 12,389 options - Feb. 16, 2021

Corcept Therapeutics Incorporated's Chief Financial Officer just disposed of 115,500 shares - Feb. 16, 2021

Joseph K. Belanoff just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 11, 2021

Renaissance Technologies LLC just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 11, 2021

Corcept Therapeutics Incorporated director just disposed of 253,712 shares - Feb. 11, 2021

INGALLS & SNYDER, LLC just provided an update on share ownership of Corcept Therapeutics Incorporated - Feb. 9, 2021

Corcept Therapeutics Incorporated's Chief Medical Officer was just granted 200,000 options - Feb. 8, 2021

Corcept Therapeutics Announces Fourth Quarter, FULL-YEAR 2020 PRELIMINARY SELECTED FINANCIAL RESULTS AND 2021 REVENUE GUIDANCE; PROVIDES CORPORATE UPDATE - Feb. 8, 2021

Corcept Therapeutics Incorporated's Chief Financial Officer was just granted 200,000 options - Feb. 8, 2021

Corcept Therapeutics Incorporated's See Remarks was just granted 200,000 options - Feb. 8, 2021

Corcept Therapeutics Incorporated's Chief Executive Officer was just granted 500,000 options - Feb. 8, 2021

Corcept Therapeutics Incorporated's Chief Scientific Officer was just granted 200,000 options - Feb. 8, 2021

Corcept Therapeutics Incorporated's Chief Accounting Officer was just granted 100,000 options - Feb. 8, 2021

Corcept Therapeutics Incorporated's Chief Accounting Officer just cashed-in 25,000 options - Feb. 4, 2021

Annual statement of changes in beneficial ownership of securities - Feb. 3, 2021

On February  - Feb. 3, 2021

Corcept Therapeutics Incorporated's Chief Executive Officer just picked up 318,912 shares - Jan. 26, 2021

BlackRock, Inc. just provided an update on share ownership of Corcept Therapeutics Incorporated - Jan. 26, 2021

Corcept Therapeutics Incorporated's Chief Financial Officer just picked up 193,113 shares - Jan. 26, 2021

Corcept Therapeutics Incorporated director just cashed-in 5,000 options - Jan. 21, 2021

Corcept Therapeutics Incorporated's Chief Accounting Officer just cashed-in 50,000 options - Jan. 4, 2021

Sorry, no schedule available for this company

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2021 Audited Financial Results and Provides Corporate Update - Feb. 15, 2022

Corcept Therapeutics to Announce Fourth Quarter and Full-year 2021 Financial Results, Provide Corporate Update and Host Conference Call - Feb. 8, 2022

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Corcept Therapeutics Incorporated (CORT) - Jan. 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT - Jan. 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT - Jan. 6, 2022

Corcept Therapeutics Announces Final Results of Previously Announced Tender Offer - Dec. 20, 2021

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Inc. on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm - Dec. 14, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Inc. - CORT - Dec. 13, 2021

Corcept Therapeutics Announces Extension of Previously Announced Tender Offer - Dec. 8, 2021

Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update - Nov. 3, 2021

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call - Oct. 27, 2021

Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer - Sept. 17, 2021

Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021 - Sept. 9, 2021

William Guyer to join Corcept as Chief Development Officer - Aug. 12, 2021

Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call - July 22, 2021

Former Gilead Sciences Executive Amy E. Flood Joins Corcept Therapeutics as Chief Human Resources and Communications Officer - July 12, 2021

Preliminary Results From RELIANT Trial of Relacorilant Plus Nab-Paclitaxel in Patients with Metastatic Pancreatic Cancer - June 22, 2021

Corcept Therapeutics Settles Patent Litigation with Sun Pharmaceutical - June 15, 2021

Corcept Therapeutics Appoints Joshua M. Murray to Board of Directors - June 10, 2021

Corcept Therapeutics Provides Clinical Update and Announces First Quarter 2021 Financial Results - May 6, 2021

 


Feedback